Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
7.00
+0.01 (0.14%)
At close: May 12, 2025, 4:00 PM
7.20
+0.20 (2.86%)
After-hours: May 12, 2025, 7:39 PM EDT
RCKT's stock price has decreased by -69.19% in the past year and price targets may not have had time to catch up.
Rocket Pharmaceuticals Analyst Ratings
Total Analysts
10
Consensus Rating
Strong Buy
Price Target
$41.70
Upside
+495.71%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $52 → $51 | Buy | Maintains | $52 → $51 | +628.57% | May 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $36 → $34 | Strong Buy | Maintains | $36 → $34 | +385.71% | May 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $54 → $45 | Strong Buy | Maintains | $54 → $45 | +542.86% | May 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $45 → $44 | Buy | Maintains | $45 → $44 | +528.57% | May 9, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $15 → $13 | Hold | Maintains | $15 → $13 | +85.71% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +500.00% | Apr 9, 2025 |
| BMO Capital | BMO Capital | Buy Initiates $50 | Buy | Initiates | $50 | +614.29% | Mar 12, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $51 → $52 | Buy | Maintains | $51 → $52 | +642.86% | Mar 3, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $29 → $15 | Hold | Maintains | $29 → $15 | +114.29% | Mar 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $39 → $36 | Strong Buy | Maintains | $39 → $36 | +414.29% | Mar 3, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $62 → $54 | Strong Buy | Maintains | $62 → $54 | +671.43% | Feb 28, 2025 |
| Needham | Needham | Strong Buy Maintains $52 → $42 | Strong Buy | Maintains | $52 → $42 | +500.00% | Feb 28, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $29 | Strong Buy | Initiates | $29 | +314.29% | Dec 18, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $39 | Strong Buy | Maintains | $39 | +457.14% | Nov 19, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $46 → $44 | Buy | Maintains | $46 → $44 | +528.57% | Nov 19, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $65 | Buy | Reiterates | $65 | +828.57% | Nov 19, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.